Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/ persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/ RAD)

1 Giu 2021

Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/ persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/ RAD)

Visualizza Documento

Condividi